Unknown

Dataset Information

0

Effects of long-term cysteamine treatment in patients with cystinosis.


ABSTRACT: Cystinosis is a rare autosomal-recessive lysosomal storage disease with high morbidity and mortality. It is caused by mutations in the CTNS gene that encodes the cystine transporter, cystinosin, which leads to lysosomal cystine accumulation. Patients with infantile nephropathic cystinosis, the most common and most severe clinical form of cystinosis, commonly present with renal Fanconi syndrome by 6-12 months of age, and without specific treatment, almost all will develop end-stage renal disease (ESRD) by 10-12 years of age. Early corneal cystine crystal deposition is a hallmark of the disease. Cystinosis also presents with gastrointestinal symptoms (e.g., vomiting, decreased appetite, and feeding difficulties) and severe growth retardation and may affect several other organs over time, including the eye, thyroid gland, gonads, pancreas, muscles, bone marrow, liver, nervous system, lungs, and bones. Cystine-depleting therapy with cysteamine orally is the only specific targeted therapy available for managing cystinosis and needs to be combined with cysteamine eye drops for corneal disease involvement. In patients with early treatment initiation and good compliance to therapy, long-term cysteamine treatment delays progression to ESRD, significantly improves growth, decreases the frequency and severity of extrarenal complications, and is associated with extended life expectancy. Therefore, early diagnosis of cystinosis and adequate life-long treatment with cysteamine are essential for preventing end-organ damage and improving the overall prognosis in these patients.

SUBMITTER: Ariceta G 

PROVIDER: S-EPMC6394685 | BioStudies | 2019-01-01

SECONDARY ACCESSION(S): 219750

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7138922 | BioStudies
2013-01-01 | S-EPMC3832870 | BioStudies
2016-01-01 | S-EPMC4884097 | BioStudies
2015-01-01 | S-EPMC4374958 | BioStudies
2021-08-02 | S-SCDT-EMM-2020-13067 | BioStudies
2016-01-01 | S-EPMC4841061 | BioStudies
2017-01-01 | S-EPMC5657490 | BioStudies
2021-06-16 | PXD020046 | Pride
2012-01-01 | S-EPMC3528584 | BioStudies
1000-01-01 | S-EPMC4328646 | BioStudies